0000899243-22-016348.txt : 20220503
0000899243-22-016348.hdr.sgml : 20220503
20220503170730
ACCESSION NUMBER: 0000899243-22-016348
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220429
FILED AS OF DATE: 20220503
DATE AS OF CHANGE: 20220503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Versant Vantage II, L.P.
CENTRAL INDEX KEY: 0001832235
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35890
FILM NUMBER: 22888169
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 415-801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Versant Vantage II GP, L.P.
CENTRAL INDEX KEY: 0001839790
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35890
FILM NUMBER: 22888168
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 415-801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Versant Vantage II GP-GP, LLC
CENTRAL INDEX KEY: 0001839789
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35890
FILM NUMBER: 22888167
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 415-801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tempest Therapeutics, Inc.
CENTRAL INDEX KEY: 0001544227
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 451472564
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT
STREET 2: SUITE 275
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-798-8589
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT
STREET 2: SUITE 275
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Millendo Therapeutics, Inc.
DATE OF NAME CHANGE: 20181207
FORMER COMPANY:
FORMER CONFORMED NAME: OvaScience, Inc.
DATE OF NAME CHANGE: 20120308
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2022-04-29
0
0001544227
Tempest Therapeutics, Inc.
TPST
0001832235
Versant Vantage II, L.P.
ONE SANSOME STREET
SUITE 3630
SAN FRANCISCO
CA
94104
0
0
1
0
0001839790
Versant Vantage II GP, L.P.
ONE SANSOME STREET
SUITE 3630
SAN FRANCISCO
CA
94104
0
0
1
0
0001839789
Versant Vantage II GP-GP, LLC
ONE SANSOME STREET
SUITE 3630
SAN FRANCISCO
CA
94104
0
0
1
0
Common Stock
2118644
D
Represents shares acquired pursuant to a Securities Purchase Agreement dated April 26, 2022 between the Issuer, Versant Vantage II, L.P. ("Vantage II") and certain other investors. Not included on this Form 3 are an additional 997,940 shares of Common Stock held by Versant Venture Capital VI, L.P. ("VVC VI"), 1,171,094 shares of Common Stock held by Versant Venture Capital IV, L.P. ("VVC IV") and 7,377 shares of Common Stock held by Versant Side Fund IV, L.P. ("VSF IV"). Vantage II, VVC VI, VVC IV and VSF IV, along with their respective general partner entities, have filed a Form 4 on the date hereof reporting their respective holdings in a consolidated filing.
These shares are held of record by Vantage II. Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP. Thomas Woiwode, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP, Vantage II GP and Thomas Woiwode disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Thomas Woiwode is a director of the Issuer and, accordingly, files separate Section 16 reports.
Versant Vantage II, L.P., By: Versant Vantage II GP, L.P. Its: General Partner, By: Versant Vantage II GP-GP, LLC Its: General Partner, By: /s/ Robin L. Praeger Its: Managing Director
2022-05-03
Versant Vantage II GP, L.P., By: Versant Vantage II GP-GP, LLC Its: General Partner, By: /s/ Robin L. Praeger Its: Managing Director
2022-05-03
Versant Vantage II GP-GP, LLC, By: /s/ Robin L. Praeger Its: Managing Director
2022-05-03